On August 7, WUXI BIO rose 3.19% in regular trading, trading at HKD 42.6/share, with turnover of HKD 233 million.

On the news front, the CXO sector continues to strengthen broadly following WuXi AppTec's robust interim results disclosure. WuXi AppTec reported H1 revenue of RMB 28.897 billion, up 38.93% year-over-year, with non-GAAP net profit surging 89.39% YoY, lifting the entire pharmaceutical outsourcing sector. On the same day, Pharmaron rose 5.30%, WuXi AppTec gained 3.17%, and WuXi XDC added 2.80%, reflecting a broad-based rally across CXO names.

Additionally, WUXI BIO's board is scheduled to review its interim results on August 25, with the market maintaining positive expectations. Institutional research indicates that the CXO upcycle has entered a profit realization phase, supported by global innovative drug primary market financing surging 58.5% YoY in H1, underpinning continued sector valuation recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)